Document is current
Any future updates will be listed below
-
Authors
Yamauchi, Nobuhiko
Mishima, Yuko
Takayama, Tomoko
Minowa, Sayuri
Morita, Yuka https://orcid.org/0009-0006-5238-2188
Momoki, Mamiko
Mima, Fuka
Teramoto, Yukako
Koba, Yusuke
Shirouchi, Yuko https://orcid.org/0000-0003-0945-2030
Ishihara, Yuko
Inoue, Norihito
Miyake, Misayo
Tsuyama, Naoko
Takeuchi, Kengo https://orcid.org/0000-0002-1599-5800
Maruyama, Dai https://orcid.org/0000-0003-0654-6920
- License Information
-
More Information
Article History
Received: 15 December 2025
Revised: 9 March 2026
Accepted: 17 March 2026
First Online: 31 March 2026
Competing interests
: DM has received consultancy from Janssen, AstraZeneca, Chugai, AbbVie, Genmab, Sanofi, BMS, and Pfizer; has received research funding from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Pfizer, Loxo Oncology, Eli Lilly, and Incyte Japan; has received honoraria from Ono, Nippon Shinyaku, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, and BeiGene. NY has received research funding from Chugai, Roche, Ono, Genmab, and Tanabe-Mitsubishi; has received honoraria from Chugai, Genmab, AbbVie, Takeda, Novartis, Mundi Pharma, Daiichi-Sankyo, Kyowa-Kirin, Johnson & Johnson, and BeiGene.
